Acquiring Company
XOMA Royalty Corporation
Acquired Company
Kinnate Biopharma
BerkeleySan DiegoBiotechnologyHealth CareBiotechnologyHealthcareHealth CareMedicalTherapeuticsDescription
XOMA Corporation has completed the tender offer to acquire all outstanding shares of Kinnate Biopharma Inc. common stock. The acquisition includes a cash amount and a non-tradeable contingent value right representing the right to receive proceeds from Kinnate's programs and assets.
Quick answer
XOMA Royalty Corporation is acquiring Kinnate Biopharma, announced April 3, 2024. XOMA Royalty Corporation is based in Berkeley, California, United States.
- How much did XOMA Royalty Corporation pay for Kinnate Biopharma?
- The deal value was not disclosed.
- What does XOMA Royalty Corporation do?
- XOMA Royalty Corporation is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health.
- Where are XOMA Royalty Corporation and Kinnate Biopharma based?
- XOMA Royalty Corporation is based in Berkeley, California, United States. Kinnate Biopharma is based in San Diego, California, United States.
- Who are the decision-makers at XOMA Royalty Corporation?
- Fundz holds 3 contacts at XOMA Royalty Corporation. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Healthcare and Medical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Johnson & Johnson (J&J) completes $12.5 Billion Acquisition of Shockwave Medical to Strengthen Cardiac Health Solutions, $13B (April 5, 2024)
- Juvisé Pharmaceuticals acquires rights to MS therapy Ponvory outside North America (April 2, 2024)
- Harmony Biosciences acquires Epygenix Therapeutics, Inc. to expand rare epilepsy franchise (April 30, 2024)
- Nuvation Bio Inc. completes acquisition of AnHeart Therapeutics Ltd. to enhance its oncology pipeline (April 10, 2024)
- Abbvie To Acquire Landos Biopharma, Further Strengthening Its Portfolio In Inflammatory And Autoimmune Diseases (March 25, 2024)
- Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction (March 25, 2024)
Who to call at XOMA Royalty Corporation, and when
When XOMA Royalty Corporation changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day XOMA Royalty Corporation raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at XOMA Royalty Corporation, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at XOMA Royalty Corporation. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment XOMA Royalty Corporation makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Kinnate Biopharma?
Kinnate Biopharma was acquired by XOMA Royalty Corporation, based in Berkeley. The deal was reported on April 3, 2024. XOMA Royalty Corporation is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty Corporation is privately held and operates in Biotechnology.
When did XOMA Royalty Corporation acquire Kinnate Biopharma?
XOMA Royalty Corporation's acquisition of Kinnate Biopharma was reported on April 3, 2024. XOMA Corporation has completed the tender offer to acquire all outstanding shares of Kinnate Biopharma Inc. common stock. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Kinnate Biopharma do?
Kinnate Biopharma Inc. is a clinical-stage precision oncology company focused on expanding on the promise of targeted therapies for those battling cancer. It is privately held, operating in Biotechnology, and is based in San Diego.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.